P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE

Benzer Materyaller

• P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
  Yazar:: Chiara Rusconi, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
  Yazar:: Armando Santoro, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-01-01)
• P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
  Yazar:: Ya.K. Mangasarova, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
  Yazar:: Chiara Rusconi, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• P124 (0115) RETROSPECTIVE REAL-LIFE STUDY OF THE BEGEV (BENDAMUSTINE, GEMCITABINE, VINORELBINE) REGIMEN IN HEAVILY PRETREATED, RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
  Baskı/Yayın Bilgisi: (2018-10-01)